Home » Stocks » MTCR

Metacrine, Inc. (MTCR)

Stock Price: $8.21 USD -0.29 (-3.41%)
Updated November 25, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 213.10M
Revenue (ttm) 2.18M
Net Income (ttm) -33.30M
Shares Out 25.96M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $8.21
Previous Close $8.50
Change ($) -0.29
Change (%) -3.41%
Day's Open 8.24
Day's Range 8.07 - 8.44
Day's Volume 65,793
52-Week Range 8.05 - 16.19

More Stats

Market Cap 213.10M
Enterprise Value 115.09M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 25.96M
Float 8.41M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 94,930
Short Ratio 0.87
Short % of Float 1.13%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 97.98
PB Ratio 2.58
Revenue 2.18M
Operating Income n/a
Net Income -33.30M
Free Cash Flow n/a
Net Cash 98.01M
Net Cash / Share 3.78
Gross Margin -1,194.16%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(149.70% upside)
Current: $8.21
Target: 20.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-1.45
Operating Income-30.00-26.73
Net Income-28.93-25.82
Shares Outstanding2.382.09
Earnings Per Share-12.17-12.35
Operating Cash Flow-27.75-25.48
Capital Expenditures-0.08-0.68
Free Cash Flow-27.83-26.16
Cash & Equivalents55.6572.99
Total Debt11.452.85
Net Cash / Debt44.2070.13
Book Value-78.24-51.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Metacrine, Inc.
Country United States
Employees 32
CEO Preston S. Klassen

Stock Information

Ticker Symbol MTCR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MTCR
IPO Date September 16, 2020


Metacrine, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.